interlymph

LATEST FINDINGS FROM THE 2017 INTERLYMPH MEETING

The 2017 InterLymph Meeting was held in Copenhagen, Denmark, 12-15 June. Lymphoma Coalition is a proud sponsor of this meeting.
The videos below feature leading researchers discussing key findings from the InterLymph working groups.

GENETICS WORKING GROUP

Genetics Update

Discussed by Susan Slager, PhD
Mayo Clinic, Rochester, Minnesota, USA

For more information, please see the following publications.

  1. Publications by Susan Slager
  2. Chronic Lymphocytic Leukemia: Prevalence, Outcomes, and Pathological Findings
  3. Relationship between co-morbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): a prospective cohort study
  4. Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia
  5. Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia
  6. Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types

HODGKIN LYMPHOMA WORKING GROUP
Hodgkin Lymphoma Update
Discussed by Ruth Jarrett, Professor of Molecular Pathology
Institute of Infection, Immunity & Inflammation, University of Glasgow, Scotland

For more information, please see the following publications.

  1. Epstein-Barr virus-associated Hodgkin's disease: Epidemiologic characteristics in international data.
  2. Impact of tumor Epstein-Barr virus status on presenting features and outcome in age-defined subgroups of patients with classic Hodgkin lymphoma: a population-based study.
  3. A Novel Risk Locus at 6p21.3 for Epstein–Barr Virus-Positive Hodgkin Lymphoma.
  4. The Role of Viruses in the Genesis of Hodgkin Lymphoma.
  5. The Chemokine CCL17/TARC as a biomarker in Hodgkin lymphoma
  6. Baseline serum TARC levels predict therapy outcome in patients with Hodgkin lymphoma.

INTERLYMPH LIFESTYLE & ENVIRONMENT WORKING GROUP
Circadian Rhythms & Lymphoma
Discussed by Neil Caporaso, MD
Senior Investigator, National Cancer Institute, Division of Cancer Epidemiology & Genetics, Occupational and Environmental Epidemiology Branch, USA

For more information, please see the following publications.

  1. PubMed publications by Neil E. Caporaso
  2. Inherited variation in circadian rhythm genes and risks of prostate cancer and three other cancer sites in combined cancer consortia.
  3. Habitual sleep and human plasma metabolomics
  4. Sleep Duration and Cancer in the NIH-AARP Diet and Health Study Cohort.
  5. Total and Cause-Specific Mortality of U.S. Nurses Working Rotating Night Shifts.
  6. Circadian disruption and cancer risk in the United States.

Occupational Risk Factors
Discussed by Pierluigi Cocco, PhD
Department of Public Health and Clinical Molecular Medicine, University of Cagliari, Italy

For more information, please see the following publications.

  1. Occupational exposure to trichloroethylene and risk of non-Hodgkin lymphoma and its major subtypes: a pooled InterLymph analysis.
  2. Lymphoma risk and occupational exposure to pesticides: results of the Epilymph study.
  3. P028 Risk of lymphoma subtypes and occupational exposure to organic dust.
  4. Occupation and Risk of Non-Hodgkin Lymphoma and Its Subtypes: A Pooled Analysis from the InterLymph Consortium.

Physical Activity & Lymphoma
Discussed by Terry Boyle, PhD
School of Public Health, Curtin University, Bentley, Australia

For more information, please see the following publications.

  1. Physical activity, obesity and survival in diffuse large B-cell and follicular lymphoma cases.
  2. Hypotheses for mechanisms linking shiftwork and cancer.
  3. Long-Term Sedentary Work and the Risk of Subsite-specific Colorectal Cancer.
  4. The association between different night shiftwork factors and breast cancer: a case–control study.
  5. Reallocating time to sleep, sedentary, and active behaviours in non-Hodgkin lymphoma survivors: associations with patient-reported outcomes.

PATHOLOGY & SURVIVAL WORKING GROUP

Risk Factors for Lymphoma
James R. Cerhan, MD, PhD
Chair of the Department of Health Sciences Research; co-leader of the Genetic Epidemiology and Risk Assessment Program; co-director of the Biorepositories Program; associate director of the Mayo Clinic Cancer Registry; Mayo Clinic, USA

For more information, please see the following publications.

 

Global Database Search

 knowyoursubtype iconb   facebook2 twitter2 youtube1

logo europe

IN THE NODE

Updates

 

The information on this website is for general use only. Please consult your physician if you think you may have lymphoma or
require more detailed information on the best course of treatment for you.

Our website does not host any form of advertisement. Last updated: 05/30/17. Copyright © 2017 Lymphoma Coalition. All rights reserved.